Lifecore Biomedical, Inc.

LFCR

US5147661046

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.595 ^USD	-0.68%		-1.42%	+6.54%

Apr. 19	Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report	MT
Apr. 01	Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024	CI

Lifecore Biomedical, Inc. Reports Earnings Results for the Fourth Quarter Ended May 28, 2023

August 31, 2023 at 07:30 am EDT

Lifecore Biomedical, Inc. reported earnings results for the fourth quarter ended May 28, 2023. For the fourth quarter, the company reported net loss was USD 36.13 million compared to USD 51.76 million a year ago. Basic loss per share from continuing operations was USD 1.11 compared to USD 0.03 a year ago.

Diluted loss per share from continuing operations was USD 1.11 compared to USD 0.03 a year ago. Basic loss per share was USD 1.19 compared to USD 1.75 a year ago. Diluted loss per share was USD 1.19 compared to USD 1.75 a year ago.

Latest news about Lifecore Biomedical, Inc.

Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report	Apr. 19	MT
Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024	Apr. 01	CI
Lifecore Biomedical Searches for New Auditor for Fiscal Year 2024	Mar. 27	MT
Top Midday Decliners	Mar. 20	MT
Lifecore Biomedical Charts Standalone Path, Names Paul Josephs as New CEO Amid Board Changes	Mar. 20	MT
Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024	Mar. 20	CI
Lifecore Biomedical, Inc. Announces Management Changes	Mar. 20	CI
Lifecore Concludes Strategic Review	Mar. 19	CI
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	Jan. 08
Sector Update: Health Care Stocks Retreat Late Afternoon	Jan. 05	MT
Sector Update: Health Care	Jan. 05	MT
Lifecore Biomedical Shares Rise Following Expansion of Alcon Contract	Jan. 05	MT
Alcon, Lifecore Biomedical Extend Contract Manufacturing Agreement	Jan. 05	MT
Lifecore Biomedical Remains Actively Engaged in its Evaluation of Potential Strategic Alternatives	Jan. 05	CI
Lifecore Biomedical, Inc. Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements	Jan. 05	CI
North American Morning Briefing : Geopolitical -2-	23-10-18	DJ
Lifecore Biomedical Enters Into Co-Marketing Partnership With SHL Medical	23-10-17	MT
SHL Medical and Lifecore Biomedical Enter Co-Marketing Partnership Agreement	23-10-17	CI
North American Morning Briefing : Stock Futures -2-	23-10-11	DJ
Lifecore Biomedical Releases Update on Timing of Delayed Filings, Development Portfolio	23-10-10	MT
North American Morning Briefing : S&P 500 Futures -2-	23-10-04	DJ
Stephens Adjusts Price Target on Lifecore Biomedical to $9 From $8, Maintains Equalweight Rating	23-09-01	MT
Barrington Trims Price Target on Lifecore Biomedical to $10 From $11, Maintains Outperform Rating	23-09-01	MT
Earnings Flash (LFCR) LIFECORE BIOMEDICAL Reports Q4 Revenue $31.5M	23-08-31	MT
Transcript : Lifecore Biomedical, Inc., Q4 2023 Earnings Call, Aug 31, 2023	23-08-31

Chart Lifecore Biomedical, Inc.

Duration

Period

More charts

Company Profile

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lifecore Biomedical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.595 USD

Average target price

6 USD

Spread / Average Target

-9.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIFECORE BIOMEDICAL, INC.	+6.54%	201M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals